Datopotamab Deruxtecan, often abbreviated as DATO, represents an important advancement in targeted cancer therapy. This novel antibody-drug conjugate joins a monoclonal antigen specifically directed at HER-2 expressing https://lucyyndu447842.wikicommunications.com/user